Influence of the age structure on the stability in a tumor-immune model for chronic myeloid leukemia

Kyriaki Dariva¹ ; Thomas Lepoutre²

¹ Univ Lyon, Université Jean Monnet Saint-Étienne, CNRS UMR 5208, Inria, Institut Camille Jordan, 42023 Saint-Etienne, France
² Univ Lyon, Inria, Université Claude Bernard Lyon 1, CNRS UMR5208, Institut Camille Jordan, 69603 Villeurbanne, France

Mathematical modelling of natural phenomena, Tome 19 (2024), article no. 1.

Résumé

In this paper a model of tumor-immune response for chronic myeloid leukemia (CML) is proposed and analyzed. It is based on the ordinary differential equations’ models (ODE) studied in A. Besse, et al., Bull. Math. Biol. (2017) 1—27, G.D. Clapp, et al., Cancer Res. 75 (2015) 4053-4062. The proliferation of cells, their differentiation in the bone marrow and the interactions of leukemic and immune cells are described. The model is based on a non-monotonic immune response. At low levels immune response increases with the tumor load, whereas at high levels tumor is suppressing the effect of the immune system (immunosuppression). We consider that the age of cells is described by a continuous variable which we use to structure the system and obtain a partial differential equations’ model (PDEs). We analyze the stability of the equilibrium points of the model and compare it to the case of A. Besse, et al., Bull. Math. Biol. (2017) 1—27 where age was described as a discrete state. In particular, an equilibrium point describing remission, induced by a control of the immune system, is shown to be unstable in certain situations for the PDE model, whereas in A. Besse, et al., Bull. Math. Biol. (2017) 1-27 it was systematically stable.

Détail

DOI : 10.1051/mmnp/2023034

Bibliographie

[1] S. Bernard, F. Crauste Optimal linear stability condition for scalar differential equations with distributed delay Discrete Continuous Dyn. Syst. B 2015 1855

[2] A. Besse, G.D. Clapp, S. Bernard, F.E. Nicolini, D. Levy, T. Lepoutre Stability analysis of a model of interaction between the immune system and cancer cells in chronic myelogenous leukemia Bull. Math. Biol. 2018 1084 1110

[3] G.D. Clapp, T. Lepoutre, R. El Cheikh, S. Bernard, J. Ruby, H. Labussière-Wallet, F.E. Nicolini, D. Levy Implication of the autologous immune system in bcr–abl transcript variations in chronic myelogenous leukemia patients treated with imatinib Cancer Res. 2015 4053 4062

[4] R.E. Clark, F. Polydoros, J.F. Apperley, D. Milojkovic, K. Rothwell, C. Pocock, J. Byrne, H. De Lavallade, W. Osborne, L. Robinson, S.G. O’Brien, L. Read, L. Foroni, M. Copland De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (destiny): a non-randomised, phase 2 trial Lancet Haematol. 2019 e375 e383

[5] M.W.N. Deininger, J.M. Goldman, J.V. Melo The molecular biology of chronic myeloid leukemia Blood 2000 3343 3356

[6] A.C. Fassoni, I. Roeder, I. Glauche To cure or not to cure: consequences of immunological interactions in cml treatment Bull. Math, Biol. 2019 2345 2395

[7] A. Gratwohl, M. Pfirrmann, A. Zander, N. Kröger, D. Beelen, J. Novotny, C. Nerl, C. Scheid, K. Spiekermann, J. Mayer Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment Leukemia 2016 562 569

[8] T. Hähnel, C. Baldow, A.C. Fassoni, J. Guilhot, F. Guilhot, S. Saussele, S. Mustjoki, S. Jilg, P.J. Jost, S. Dulucq, F.-X. Mahon, I. Roeder and I. Glauche, Inferring immunological control mechanisms from TKI dose alterations in cml patients. bioRxiv, 2019.

[9] T. Hähnel, C. Baldow, J. Guilhot, F. Guilhot, S. Saussele, S. Mustjoki, S. Jilg, P.J. Jost, S. Dulucq, F.-X. Mahon Model-based inference and classification of immunologic control mechanisms from TKI cessation and dose reduction in patients with cml Cancer Res. 2020 2394 2406

[10] R. Hehlmann, U. Berger, M. Pfirrmann, H. Heimpel, A. Hochhaus, J. Hasford, H.-J. Kolb, T. Lahaye, O. Maywald, A. Reiter Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia Blood 2007 4686 4692

[11] A. Hochhaus, M. Baccarani, R.T. Silver, C. Schiffer, J.F. Apperley, F. Cervantes, R.E. Clark, J.E. Cortes, M. Deininger, F. Guilhot European leukemianet 2020 recommendations for treating chronic myeloid leukemia Leukemia 2020 966 984

[12] M. Ilander, U. Olsson-Straömberg, H. Schlums, J. Guilhot, O. Brüack, H. Lähteenmäki, T. Kasanen, P. Koskenvesa, S. Söaderlund, M. Höglund Increased proportion of mature nk cells is associated with successful imatinib discontinuation in chronic myeloid leukemia Leukemia 2017 1108 1116

[13] P. Jain, H.M. Kantarjian, A. Ghorab, K. Sasaki, E.J. Jabbour, G. Nogueras Gonzalez, R. Kanagal-Shamanna, G.C. Issa, G. Garcia-Manero, D. Kc Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients Cancer 2017 4391 4402

[14] F.-X. Mahon, D. Réa, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, L. Legros, A. Charbonnier, A. Guerci, B. Varet, G. Etienne, J. Reiffers, P. Rousselot Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (stim) trial Lancet Oncol. 2010 1029 1035

[15] F. Michor, T.P. Hughes, Y. Iwasa, S. Branford, N.P. Shah, C.L. Sawyers, M.A. Nowak Dynamics of chronic myeloid leukaemia Nature 2005 1267 1270

[16] K.-J.E.R. Nagel, One-parameter Semigroups for Linear Evolution Equations, Vol. 194. Springer-Verlag New York (2000).

[17] D. Rea, G. Henry, Z. Khaznadar, G. Etienne, F. Guilhot, F. Nicolini, J. Guilhot, P. Rousselot, F. Huguet, L. Legros Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the immunostim study Haematologica 2017 1368 1377

[18] I. Roeder, M. Horn, I. Glauche, A. Hochhaus, M. C. Mueller, M. Loeffler Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications Nat Med 2006 1181 1184

[19] S. Saussele, J. Richter, A. Hochhaus, F. Mahon The concept of treatment-free remission in chronic myeloid leukemia Leukemia 2016 1638 1647

[20] G. Stépán, Retarded Dynamical Systems: Stability and Characteristic Functions. Longman Scientific Technical (1989).

[21] A. Yong and A. Hughes, Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front. Immunol. 8 (2017).